ReportGemReportGem 中文

PUBLIC COMPANY RESEARCH HUB

GILD.OQ (GILD.OQ) Foreign Research Coverage

A focused collection of foreign research coverage for GILD.OQ, organized by institution and publication date for faster discovery.

Evidence documents5
Filings0
Meetings0
Research5
Displayed research share100%
Latest evidence2026-08-05

Foreign research

Gilead Sciences Inc.: 2Q決算はおそらく十分な内容2026-08-05 · Morgan Stanley

M Idea 2026 年 8 月 5 日 08:14 AM GMT Morgan Stanley & Co. LLC Gilead Sciences Inc. | North America Terence C Flynn, Ph.D. 株式アナリスト 2Q決算はおそらく十分な内容 Chris Yu, J.D., Ph.D. 株式アナリスト Connor M Massari AlphaSignals 決算リアクション 株式アナリスト 影響なし 小幅超過 小幅な上振れ 弊社シナリオへの影響 実績VSコンセンサス …

Gilead Sciences Inc.: 2Q likely good enough2026-08-05 · Morgan Stanley

M Idea August 5, 2026 03:11 AM GMT Morgan Stanley & Co. LLC Gilead Sciences Inc. | North America Terence C Flynn, Ph.D. Equity Analyst 2Q likely good enough Chris Yu, J.D., Ph.D. Equity Analyst Connor M Massari AlphaSignals Earnings Reaction Equity Analyst …

Gilead Sciences 2Q26 Takeaways – Raising Estimates After Another Strong HIV Qtr2026-08-05 · JPMorganFirst Read: Gilead Sciences "CA supreme court dismissed the FTD case entirely…"2026-08-03 · UBS EquitiesGILD: Yeztugo 2Q26 Preview: Rx Growth Softening, Though Channel Mix and FAERS Data Tell More Complex Story2026-07-23 · RBC Capital Markets

Questions this evidence can help answer

  • What changed in the latest research coverage of GILD.OQ?
  • Which operating and valuation themes recur across institutions?
  • Which claims should be checked against company primary-source evidence?
Research this company with AI